D-0114-2026 Class II Ongoing

Recalled by ProRx LLC — Exton, PA

FDA drug recall D-0114-2026 was initiated by ProRx LLC on Oct 15, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing. Affected quantity: 2,809 vials.

Recall details

Product Type
Drugs
Report Date
Nov 5, 2025
Initiation Date
Oct 15, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,809 vials

Product description

Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

TX and UT

Code information

Lot# Prorx04282025-3

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0114-2026
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0114-2026. Report a data issue: hello@regdatalab.com.